Status:
COMPLETED
Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Lead Sponsor:
University of Michigan
Conditions:
Cystic Fibrosis
Lung Transplant
Eligibility:
All Genders
18-70 years
Brief Summary
Lung transplantation is a life saving procedure for patients with a terminal lung disease such as cystic fibrosis. Approximately, one in 3,500 children in the United States are born with cystic fibros...
Detailed Description
Background: Lung transplantation has been established as a viable treatment for cystic fibrosis (CF) patients who have end-stage lung disease. CF is a genetic disorder which is caused by mutations in...
Eligibility Criteria
Inclusion
- Ability and willingness to provide informed consent and be compliant with the study procedures
- Between 18-70 years of age
- Greater than 1 year post-transplant
- Have no evidence of acute rejection at 1 year post-transplant biopsy or within three months of study entry
- Stable mycophenolate mofetil dose
- Stable renal function
Exclusion
- Serum creatinine greater than 2 mg/dl
- Received pulse steroids within 3 months of the study entry
- Chronic diarrhea
- Concurrently on interacting medications (cholestyramine, etc)
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00908830
Start Date
June 1 2009
End Date
May 1 2011
Last Update
August 6 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.